New Opioid-Like drug put to the test: will it be less addictive?

NCT ID NCT06453265

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new painkiller called cebranopadol, given as a nasal spray, to see how much recreational opioid users liked it compared to oxycodone and a placebo. 48 healthy volunteers who had used opioids for fun in the past took part. The goal was to measure the drug's abuse potential, which could help develop safer pain medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cebranopadol

What this could lead to

If cebranopadol shows lower abuse potential than oxycodone, it could point toward a safer painkiller with less risk of addiction.

What could go wrong

This is a small, early-phase study in healthy recreational users, not patients in pain. Results may not predict real-world abuse or safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABUSE, DRUG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

substance abuse substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ohio Clinical Trials, Inc.

    Columbus, Ohio, 43212, United States